Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: Results from two phase III clinical trials

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 7, 2011, Pages 851-857

  Guenther, L ^a   Han, C ^b   Szapary, P ^c   Schenkel, B ^b   Poulin, Y ^d   Bourcier, M ^e   Ortonne, J P ^f   Sofen, H L ^g  

^a Guenther Dermatology Research Centre   (Canada)

^b Johnson and Johnson Pharmaceutical Services   (United States)

^c CENTOCOR INC   (United States)

^d Centre Dermatologique du Quebec Metropolitain   (Canada)

^e Dermatology Clinic   (Canada)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g Dermatology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; USTEKINUMAB;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMYELINATING DISEASE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIOSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SALMONELLOSIS; SELF REPORT; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; PSORIASIS; QUALITY OF LIFE; SEXUALITY;

EID: 79959816954     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04082.x     Document Type: Article

References (36)

1. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-1912.
2. National Psoriasis Foundation. About psoriasis: statistics. 2010. URL http://www.psoriasis.org/about/stats (last accessed: 29 March 2010).
3. Gelfand JM, Feldman SR, Stern RS et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704-708. (Pubitemid 39516879)
4. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-244.
5. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
6. Kimball AB, Jacobson C, Weiss S et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392. (Pubitemid 43128290)
7. Türel Ermertcan A, Temeltas G, Deveci A et al. Sexual dysfunction in patients with psoriasis. J Dermatol 2006; 33: 772-778. (Pubitemid 44630140)
8. Sampogna F, Gisondi P, Tabolli S, Abeni D. Impairment of sexual life in patients with psoriasis. Dermatology 2007; 214: 144-150. (Pubitemid 46377240)
9. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 1997; 36: 259-262. (Pubitemid 27242616)
10. Esposito M, Saraceno R, Giunta A et al. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123-127. (Pubitemid 43260727)
11. Cohen AD, Ofek-Shlomai A, Vardy DA et al. Depression in dermatological patients identified by the Mini International Neuropsychiatric Interview questionnaire. J Am Acad Dermatol 2006; 54: 94-99. (Pubitemid 41832464)
12. Aktan Ş, Özmen E, Şanli B. Psychiatric disorders in patients attending a dermatology outpatient clinic. Dermatology 1998; 197: 230-234. (Pubitemid 28445820)
13. Weiss SC, Kimball AB, Liewehr DJ et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-518.
14. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis, and psoriasis. Br J Dermatol 1998; 139: 846-850. (Pubitemid 28520293)
15. Picardi A, Mazzotti E, Pasquini P. Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol 2006; 54: 420-426. (Pubitemid 43243444)
16. Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217. (Pubitemid 40202906)
17. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-496. (Pubitemid 26249398)
18. Meeuwis KAP, De Hullu JA, Van de Nieuwenhof HP et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. Published online: February 17, 2011. doi: 10.1111/j.1365-2133.2011.10249.x
19. Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol 2007; 25: 547-554. (Pubitemid 350087601)
20. Schmid-Ott G, Jaeger B, Kuensebeck HW, Ott R, Lamprecht F. Dimensions of stigmatization in patients with psoriasis in a 'Questionnaire on Experience with Skin Complaints'. Dermatology 1996; 193: 304-310.
21. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674. (Pubitemid 351671883)
22. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
23. Lebwohl M, Papp K, Han C et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-146.
24. Langley RG, Feldman SR, Han C et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-465.
25. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
26. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210: 194-199. (Pubitemid 40529233)
27. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. (Pubitemid 24194579)
28. Reich K, Sinclair R, Roberts F et al. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin 2008; 24: 1237-1254. (Pubitemid 351741556)
29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370. (Pubitemid 13098606)
30. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, NJ, 1988.
31. Rosenthal R, Rosnow RL. Essentials of Behavioral Research: Methods and Data Analysis. McGraw-Hill, New York, NY, 1984.
32. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999; 56: 201-208. (Pubitemid 30058223)
33. Reynolds OD. Erectile dysfunction in etretinate treatment. Arch Dermatol 1991; 127: 425-426.
34. Aguirre MA, Vélez A, Romero M, Collantes E. Gynecomastia and sexual impotence associated with methotrexate treatment. J Rheumatol 2002; 29: 1793-1794. (Pubitemid 34831258)
35. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640.
36. Lebwohl M, Papp K, Han C et al. Ustekinumab reduces itch, bodily pain, and fatigue in patients with moderate to severe psoriasis. ISPOR 14th Annual International Meeting, May 2009. Orlando, FL. Abstract.